



**FOR IMMEDIATE RELEASE**

## **LMA ACQUIRES INNOVATIVE PATIENT WARMING DEVICE FOR US\$3.7 MILLION**

**Singapore, 15 October 2007** – Singapore-listed LMA International N.V. (“LMA” or the “Group”), a global leader in the development and marketing for the LMA™ laryngeal mask airway range of supraglottic airway management devices, announced that it has acquired the intellectual property and distribution rights to an innovative patient warming device from an American inventor. Known as “*PerfecTemp*,” the device is a warming and pressure reduction pad which is expected to dramatically reduce the risk of post-operative hypothermia in patients who undergo surgical procedures involving general anaesthesia.

LMA’s wholly owned subsidiary, LMA Medical Innovations Ltd., a company incorporated in the Seychelles, has entered into a sale and purchase agreement to acquire the exclusive intellectual property and distribution rights to *PerfecTemp* for a total potential consideration of US\$3.7 million. An initial sum of US\$746,000 is payable in the first six months, with the remainder paid based on sales achievements over a period of seven years. The total consideration is capped at US\$3.7 million.

The *PerfecTemp* patient warming and pressure reduction pad is a breakthrough in the ease and effectiveness in patient warming that will enable operating room clinicians to reduce the risk of post-operative hypothermia. The device is designed to be permanently placed on the operating table, allowing warming to be continuously available to patients with minimal clinician intervention. Moreover, because it is reusable, it can warm patients at a cost well below that of currently available disposable patient warming products.

Steven R. Block, President and CEO of LMA North America, said, “It is well documented that post-operative hypothermia increases the likelihood of complications such as infection and prolongs patient recovery time. Despite this, less than half of surgical patients are routinely warmed. The *PerfecTemp* system will make patient warming a basic standard for every person who undergoes a surgical procedure.”

Currently, the market for patient warming products is estimated to be US\$300 million worldwide. The size of this market is expected to grow as healthcare quality organizations and government agencies increasingly focus on the issue.

John Lim, LMA’s Deputy Executive Chairman, added, “*PerfecTemp* will be manufactured in the United States and Singapore, and represents another success in identifying and

acquiring new and innovative medical devices which are synergistic to our existing products and which will broaden our offerings and business base. This product capitalises on our strong relationships with anaesthetists in operating rooms around the world and the reach of our global distribution network. It will expand the basket of LMA products they can use.”

The device has already obtained FDA approval in the United States, and approval for CE marking will be sought in the first quarter of 2008.

- Ends -

**For media queries, please contact**

Sharon Seetho, Gavin Anderson & Company, Singapore, +65 6339 9110

**About LMA**

Incorporated in the Netherlands Antilles in 1998, LMA listed on the Mainboard of the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany, San Diego, California and Melbourne, Australia. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Gland, Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.